| |
Chengdu Institute Of Chiral Material Medica Co., Ltd. Email: cicmm@cicmmpharm.com (CICMM) are mainly engaged in R&D of New Drug, like development of innovative drug or new drug with independent intellectual property. CICMM also own international and domestic invention patent 33 items, and HI-TECH achievements 4 items, is the world leader in raw materials, intermediates, fine chemistry, APIs and more. Our R&D team specializes in pharmaceutical synthesis, development of chiral material, pharmaceutical analysis, pharmacological study, project management, with over 15 staff who are profound and experienced in the field of clinical medicine and pharmacy. We also built partnerships with many companies at home and abroad, jointly establishing screening platform of synthetic drug and natural medicine, innovation platform of preparation and medicine. Up to now, CICMM have got New Drug's Certificates 44 items. CICMM have administration, warehousing and international trade office in Chengdu, R&D lab in Hangzhou. Our purpose is to make discoveries of new life science possible by providing the highest performing and most innovative range of fine chemicals、pharmaceutical intermediates available worldwide. CICMM’s main business stretches to
Lawesson's reagent, CAS 19172-47-5,
（S）-1-phenyl-1,2,3,4-tetrahydroisoquinoline,
CAS 118864-75-8,
Febuxostat,
Venlafaxine, CAS 93413-69-5,
Rocuronium bromide, CAS 119302-91-9,
Flumazenil, CAS 78755-81-4,
5-HTP, 5-hydroxytryptophan, CAS 56-69-9
And so on.
If you are interested in our products, please contact us by email or phone. CICMM wishes to establish steady relation with both the domestic and international customers, waiting for your kindly comments!
|
|
